SNGX News and Press, Soligenix Inc. From 10/05/22

Summary Soligenix is an underfollowed biotech company trading at a $20 million market cap. The company is about to file an NDA for HyBryte, which I expect to become a first-in-class treatment in cutaneous T-cell lymphoma. The company’s heat-stable vaccine development pr...

Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting PR Newswire - Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time - Soligenix encourages all stockholders of record at the ...

Soligenix ( NASDAQ: SNGX ) is trading 3.2% higher after the U.S. Food and Drug Administration awarded a $2.6M grant to support a study of expanded HyBryte treatment to treat T-cell lymphoma, including at-home usage. HyBryte is a skin directed photodynamic...

New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the FDA to support a study of expanded HyBryte™ treatment, including at-home usage. The F...

Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire PRINCETON, N.J. , Sept. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on d...

Clinical-stage biotech Soligenix, Inc. ( NASDAQ: SNGX ) announced Tuesday that the FDA had awarded a $2.6M grant to support studies for its experimental therapy HyBryte for expanded treatment in early-stage cutaneous T-Cell Lymphoma (CTCL). A photodynamic therapy, HyBryte,...

U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Grant supports study of expanded HyBryte™ treatment, including in the Home U...

Soligenix press release ( NASDAQ: SNGX ): Q2 GAAP EPS of -$0.06 beats by $0.03 . Revenue of $0.4M (+100.0% Y/Y) beats by $0.2M . As of June 30, 2022, the Company's cash position was approximately $20.2 million. Shares +5% PM. For further details s...

Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results PR Newswire PRINCETON, N.J. , Aug. 12, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on d...

Soligenix ( NASDAQ: SNGX ) said it received agreement from the U.S. Food & Drug Administration (FDA) on an initial pediatric study plan ((iPSP)) of its photodynamic therapy HyBryte (synthetic hypericin) to treat cutaneous T-cell lymphoma (CTCL). The iPSP stipu...